Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.59 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079898 | 0.93 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11CDK9 | |
| SCHEMBL2079373 | 0.93 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11CDK9 | |
| SCHEMBL2079056 | 0.89 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK9 | |
| SCHEMBL2079268 | 0.85 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11CDK9 | |
| SCHEMBL2079289 | 0.84 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK9 | |
| SCHEMBL2080269 | 0.84 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CDK9 | |
| SCHEMBL4076075 | 0.83 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4385651 | 0.83 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2081062 | 0.80 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2828324 | 0.80 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | claimed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | claimed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | claimed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | claimed |
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | MAPK14 23/4885MAPK13 38/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.